To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM
1. Age ≥45 years to 75 years of age 2. Diagnosed with sIBM based on the ENMC IBM Research Diagnostic Criteria 3. Willing and able to comply with clinic visits and study-related procedures. 4. Provide informed consent signed by the study patient or legally acceptable representative.
Intravaginal
Transdermal
Oral
1. Other neurological conditions (e.g., hemiplegia post-stroke, Parkinson's Disease) or musculoskeletal conditions (e.g., severe osteoarthritis) causing mobility impairment.
Austin Neuromuscular Center
Lead sponsor
Regeneron Pharmaceuticals
Collaborator